| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NSC-87877 | GDSC1000 | pan-cancer | AAC | 0.053 | 0.2 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | Tipifarnib | FIMM | pan-cancer | AAC | 0.19 | 0.2 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | isoliquiritigenin | CTRPv2 | pan-cancer | AAC | -0.091 | 0.2 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |